Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire

Abstract

Background Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory musculoskeletal disease, manifesting as peripheral arthritis, enthesitis, dactylitis, spondylitis, and skin and nail psoriasis. A core set of domains for measuring the impact of PsA has been developed, including pain, patient global assessment, physical function, health-related quality of life (HRQoL), and fatigue. To understand the impact of PsA on health domains from a patient’s perspective, a global survey was developed and results reported in the context of the 12-item Psoriatic Arthritis Impact of Disease (PsAID-12) questionnaire. Methods An online patient-based global survey was conducted by The Harris Poll in Australia, Brazil, Canada, France, Spain, Taiwan, the UK, and the US between November 2, 2017 and March 12, 2018. Eligible patients were ≥ 18 years old with a diagnosis of PsA for > 1 year, had visited a rheumatologist/dermatologist in the past 12 months and reported using ≥ 1 synthetic/biologic disease-modifying antirheumatic drug for PsA. Patients reported on PsA severity and symptoms, and the impact of PsA on HRQoL. After survey completion, responses were aligned with PsAID health domains. Descriptive statistics and chi-square tests were conducted. Results This analysis included 1286 patients from eight countries. Most patients (97%) reported musculoskeletal symptoms relating to PsA in the past year. Common moderate/major impacts of PsA were on physical activity (78%), ability to perform certain activities (76%), work productivity (62%), and career path (57%). Skin/nail symptoms occurred in 80% of patients. Overall, 69% of patients reported that PsA had a moderate/major impact on emotional/mental wellbeing, 56% on romantic relationships/intimacy, and 44% on relationships with family and friends. Social impacts included emotional distress (58%), social shame or disapproval (32%), and ceased participation in social activities (45%). Over half of all patients experienced unusual fatigue over the past 12 months (52%). The health domains that patients reported as being impacted by PsA aligned with life impact domains of the patient-derived PsAID health domains. Conclusion These results highlight the impact of PsA on multiple health domains from a patient perspective that should be considered during shared decision-making processes between healthcare providers and patients.

Patient Perceptions of Psoriatic Arthritis Management and Communication with Physicians in Australia: Results from a Patient Survey

“…After weighted data were adjusted to account for the relative size of the country’s adult population within the total adult population for the global survey, the sample size for patients in Australia was 39. The global population consisted of 1286 patients, and these data are presented in detail elsewhere [ 12 ]. Patient demographics and disease characteristics for patients in Australia and the global patient population are described in the electronic supplementary material (Table S1).…”

“…Global data are presented in the electronic supplementary material (Table S1) and described in detail elsewhere [ 12 ]. Demographic characteristics were generally comparable with patients in Australia, except for a higher proportion of patients with a current prescription of only biologic DMARDs in the global population (38% [global] vs. 19% [Australia]).…”

“…However, a patient’s perception of disease remission or disease activity may differ from the perception of their HCP, and communication between a patient and their HCP is not always optimal [ 10 ]. A global and country-specific survey was conducted by The Harris Poll on behalf of Pfizer Inc (PsA narrative global patient survey) to determine the impact of PsA on daily life from the patient’s perspective [ 12 ]. Here, we present data from The Harris Poll on perceptions of PsA treatment and satisfaction with HCP communication among patients in Australia with PsA.…”

Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2

“…PROs reflect many important issues that significantly impact patients with PsA, including challenges in mental, physical, and social functioning, pain, fatigue, work-related disability, in addition to psoriatic, axial, and skin disease symptoms. Many of these symptoms and sequelae of disease are represented by the core domains recommended by the GRAPPA-OMERACT working group to be measured in all RCTs to evaluate treatment efficacy [2,3,18,[37][38][39][40]. In a recent qualitative interview study of PsA patients recruited through the FORWARD databank, joint pain and stiffness, skin symptoms, fatigue, and physical disability were identified as some of the most salient PsA symptoms [39].…”

Patient-Centered Care in Psoriatic Arthritis—A Perspective on Inflammation, Disease Activity, and Psychosocial Factors

“…Mood and sleep disorders, fatigue, and employment status are all independently related to QoL in PsA [ 23 ]. PsA impacts emotional, social, and work-related aspects of life even when treated [ 24 ], which shows that improving one domain of disease (i.e., inflammatory activity) does not immediately yield benefits in others. PsA shares a different pattern of QoL impairment from other inflammatory arthritides [ 25 ].…”